

IFW

CASE QA0286 NP



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mary K. VanAtten  
Type or print name

*Mary VanAtten*  
Signature

3/14/05  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CARTER ET AL.

APPLICATION NO: 10/776,586

FILED: FEBRUARY 11, 2004

FOR: LACTAMS AS MODULATORS OF CHEMOKINE RECEPTOR  
ACTIVITY

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. § 1.98 (a)(2)(iii), applicant wishes to call the Examiner's attention to related applications: 10/922,406 (7508) filed on 08/19/04, 10/923,619 (QA0294) filed on 08/19/04; 10/923,538 (10023) filed on 08/19/04; 10/776,828 (7442) filed on 02/11/04 and WO2004/071460.


Also, applicant wishes to call the Examiner's attention to related applications: US20050043392A1; U.S. 6,706,712 B2; US20040110736A1 and WO 02/060859; US20030216434A1 and WO 03/075853; US20040235835A1 and WO 2004/098512; US20040235836A1 and WO 2004/098516; US20030060459A1 and WO02/50019

One of the enclosed references were cited in a search report in a corresponding PCT International application. A copy of the reference and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-4379

  
\_\_\_\_\_  
Mary K. VanAtten  
Attorney for Applicants  
Reg. No. 39,408

Date: March 14, 2005

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
QA0286 NP  
APPLICATION NO.  
10/776,586  
APPLICANT  
Carter et al.  
FILING DATE  
02/11/2004

Group

## U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		U.S. APPLICATION	DATE OF FILING	NAME	CLASS	SUBCLASS	FILING DATE
	AB	10/922,406	08/19/04	Carter et al.			
	AC	10/923,619	08/19/04	Carter et al.			
	AD	10/923,538	08/19/04	Carter et al.			
	AE	10/776,828	2/11/04	Cherney et al.			

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AF	US20040110736A1	06/10/04	Cherney			
	AG	US20040235836A1	11/25/04	Cherney			
	AH	US20040235835A1	11/25/04	Carter			
	AI	US20050043392A1	2/24/05	Carter			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AJ	Cregge et al., "Inhibition of Human Neutrophil Elastase. 4. Design, Synthesis, X-ray Crystallographic Analysis, and Structure-Activity Relationships for a Series of P <sub>2</sub> -Modified, Orally Active Peptidyl Pentafluoroethyl Ketones", <i>J. Med. Chem.</i> , Vol. 41, pp. 2461-2480, 1998.

EXAMINER

DATE CONSIDERED

